CN102675205B - 一种吡唑肟醚类化合物及其制备与在抗癌治疗中的应用 - Google Patents
一种吡唑肟醚类化合物及其制备与在抗癌治疗中的应用 Download PDFInfo
- Publication number
- CN102675205B CN102675205B CN201210164988.6A CN201210164988A CN102675205B CN 102675205 B CN102675205 B CN 102675205B CN 201210164988 A CN201210164988 A CN 201210164988A CN 102675205 B CN102675205 B CN 102675205B
- Authority
- CN
- China
- Prior art keywords
- oxime ether
- preparation
- reaction
- ether derivatives
- solid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- -1 Pyrazol oxime ether compound Chemical class 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title abstract description 50
- 238000011319 anticancer therapy Methods 0.000 title abstract description 6
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Natural products CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 claims description 43
- 238000006243 chemical reaction Methods 0.000 claims description 33
- 239000007787 solid Substances 0.000 claims description 24
- 239000000243 solution Substances 0.000 claims description 18
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 17
- 229940040526 anhydrous sodium acetate Drugs 0.000 claims description 16
- 239000003960 organic solvent Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- 239000012043 crude product Substances 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 12
- 238000001953 recrystallisation Methods 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 11
- JOVOSQBPPZZESK-UHFFFAOYSA-N phenylhydrazine hydrochloride Chemical compound Cl.NNC1=CC=CC=C1 JOVOSQBPPZZESK-UHFFFAOYSA-N 0.000 claims description 10
- 229940038531 phenylhydrazine hydrochloride Drugs 0.000 claims description 10
- 150000008062 acetophenones Chemical class 0.000 claims description 9
- 238000004440 column chromatography Methods 0.000 claims description 9
- 239000012044 organic layer Substances 0.000 claims description 8
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 claims description 7
- 238000000746 purification Methods 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 239000002274 desiccant Substances 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 238000003828 vacuum filtration Methods 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 abstract description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 abstract description 3
- 201000010881 cervical cancer Diseases 0.000 abstract description 3
- 239000002246 antineoplastic agent Substances 0.000 abstract description 2
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 2
- 230000004663 cell proliferation Effects 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 description 29
- HYDZPXNVHXJHBG-UHFFFAOYSA-N o-benzylhydroxylamine;hydron;chloride Chemical compound Cl.NOCC1=CC=CC=C1 HYDZPXNVHXJHBG-UHFFFAOYSA-N 0.000 description 26
- 239000013078 crystal Substances 0.000 description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 11
- SQDFHQJTAWCFIB-UHFFFAOYSA-N n-methylidenehydroxylamine Chemical compound ON=C SQDFHQJTAWCFIB-UHFFFAOYSA-N 0.000 description 9
- GNKZMNRKLCTJAY-UHFFFAOYSA-N 4'-Methylacetophenone Chemical compound CC(=O)C1=CC=C(C)C=C1 GNKZMNRKLCTJAY-UHFFFAOYSA-N 0.000 description 8
- NTPLXRHDUXRPNE-UHFFFAOYSA-N 4-methoxyacetophenone Chemical compound COC1=CC=C(C(C)=O)C=C1 NTPLXRHDUXRPNE-UHFFFAOYSA-N 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- ZDPAWHACYDRYIW-UHFFFAOYSA-N 1-(4-fluorophenyl)ethanone Chemical compound CC(=O)C1=CC=C(F)C=C1 ZDPAWHACYDRYIW-UHFFFAOYSA-N 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 5
- 229910052731 fluorine Inorganic materials 0.000 description 5
- 239000011737 fluorine Substances 0.000 description 5
- YEUNNNXEJUBNCO-UHFFFAOYSA-N n-phenylmethoxymethanimine Chemical compound C=NOCC1=CC=CC=C1 YEUNNNXEJUBNCO-UHFFFAOYSA-N 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- HFZNWDNDGDEBBV-UHFFFAOYSA-N o-[(2,4-dichlorophenyl)methyl]hydroxylamine;hydrochloride Chemical compound Cl.NOCC1=CC=C(Cl)C=C1Cl HFZNWDNDGDEBBV-UHFFFAOYSA-N 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- JCQPJRVOBJXMRB-UHFFFAOYSA-N n-[(2,4-dichlorophenyl)methoxy]methanimine Chemical compound ClC1=CC=C(CON=C)C(Cl)=C1 JCQPJRVOBJXMRB-UHFFFAOYSA-N 0.000 description 4
- BUZYGTVTZYSBCU-UHFFFAOYSA-N 1-(4-chlorophenyl)ethanone Chemical compound CC(=O)C1=CC=C(Cl)C=C1 BUZYGTVTZYSBCU-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229960004756 ethanol Drugs 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 150000003217 pyrazoles Chemical class 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N Aminoantipyrine Natural products CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 1
- STPLKWGZACWGKV-VULFUBBASA-N Clc1cc(Cl)c(CO/N=C/c2c[n](-c3ccccc3)nc2-c2ccccc2)cc1 Chemical compound Clc1cc(Cl)c(CO/N=C/c2c[n](-c3ccccc3)nc2-c2ccccc2)cc1 STPLKWGZACWGKV-VULFUBBASA-N 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- LWFQJKOJNPOYCU-UHFFFAOYSA-N N=C(/C(/C=N/[O-]Cc(cccc1)c1F)=C\[N-]c1ccccc1)c(cc1)ccc1F Chemical compound N=C(/C(/C=N/[O-]Cc(cccc1)c1F)=C\[N-]c1ccccc1)c(cc1)ccc1F LWFQJKOJNPOYCU-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229960005222 phenazone Drugs 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210164988.6A CN102675205B (zh) | 2012-05-25 | 2012-05-25 | 一种吡唑肟醚类化合物及其制备与在抗癌治疗中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210164988.6A CN102675205B (zh) | 2012-05-25 | 2012-05-25 | 一种吡唑肟醚类化合物及其制备与在抗癌治疗中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102675205A CN102675205A (zh) | 2012-09-19 |
CN102675205B true CN102675205B (zh) | 2014-08-20 |
Family
ID=46807827
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210164988.6A Expired - Fee Related CN102675205B (zh) | 2012-05-25 | 2012-05-25 | 一种吡唑肟醚类化合物及其制备与在抗癌治疗中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102675205B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104725366B (zh) * | 2015-02-28 | 2018-06-19 | 南通大学 | 含5-烷氧基噻二唑结构的三氟甲基吡唑肟类衍生物的制备方法和用途 |
CN105712932B (zh) * | 2016-03-08 | 2019-01-22 | 南通大学 | 一种含1-甲基-3-芳基-4-氯吡唑结构的吡唑肟醚化合物的制备和应用 |
CN111518084B (zh) * | 2020-05-21 | 2022-08-09 | 南通大学 | 一种含嘧啶杂环单元的吡唑衍生物及其制备方法和应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4963575A (en) * | 1988-07-15 | 1990-10-16 | May & Baker Ltd. | Derivatives of N-phenylpyrazoles, compositions and use |
US5916618A (en) * | 1985-12-20 | 1999-06-29 | Rhone-Poulenc Agriculture Ltd. | Derivatives of N-phenylpyrazoles |
CN1704414A (zh) * | 2004-05-28 | 2005-12-07 | 贵州大学 | 1-芳基吡唑肟类衍生物及其制备和应用 |
CN1844103A (zh) * | 2006-03-22 | 2006-10-11 | 南开大学 | 吡唑肟醚类衍生物和制备及其应用 |
CN101973934A (zh) * | 2010-09-06 | 2011-02-16 | 贵州大学 | 1,5-二取代芳基-1,4-戊二烯-3-酮肟醚类化合物及其制备方法和杀虫活性应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03240775A (ja) * | 1990-02-16 | 1991-10-28 | Ube Ind Ltd | ピラゾールオキシム誘導体及び殺虫・殺ダニ・殺菌剤 |
-
2012
- 2012-05-25 CN CN201210164988.6A patent/CN102675205B/zh not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5916618A (en) * | 1985-12-20 | 1999-06-29 | Rhone-Poulenc Agriculture Ltd. | Derivatives of N-phenylpyrazoles |
US4963575A (en) * | 1988-07-15 | 1990-10-16 | May & Baker Ltd. | Derivatives of N-phenylpyrazoles, compositions and use |
CN1704414A (zh) * | 2004-05-28 | 2005-12-07 | 贵州大学 | 1-芳基吡唑肟类衍生物及其制备和应用 |
CN1844103A (zh) * | 2006-03-22 | 2006-10-11 | 南开大学 | 吡唑肟醚类衍生物和制备及其应用 |
CN101973934A (zh) * | 2010-09-06 | 2011-02-16 | 贵州大学 | 1,5-二取代芳基-1,4-戊二烯-3-酮肟醚类化合物及其制备方法和杀虫活性应用 |
Non-Patent Citations (14)
Title |
---|
GUIPING OUYANG,等.Synthesis and Antiviral Activities of Pyrazole Derivatives Containing an Oxime Moiety.《J. Agric. Food Chem.》.2008,第56卷(第21期),第10160-10167页. |
HONG DAI,等.Synthesis and Biological Activities of Novel Pyrazole Oxime Derivatives Containing a 2-Chloro-5-thiazolyl Moiety.《J. Agric. Food Chem.》.2008,第56卷(第22期),第10805-10810页. |
Hyun-Ja Park, 等.Identification of antitumor activity of pyrazole oxime ethers.《Bioorganic & Medicinal Chemistry Letters》.2005,第15卷(第13期),第3307–3312页. |
Hyun-Ja Park, 等.Identification of antitumor activity of pyrazole oxime ethers.《Bioorganic & * |
JP平3-240775A 1991.10.28 |
Medicinal Chemistry Letters》.2005,第15卷(第13期),第3307–3312页. * |
N-取代-5-磺酰基吡唑肟酯衍生物的合成及生物活性研究;史大斌,等;《遵义医学院学报》;20080630;第31卷(第03期);第228-230页 * |
Synthesis and Antiviral Activities of Pyrazole Derivatives Containing an Oxime Moiety;GUIPING OUYANG,等;《J. Agric. Food Chem.》;20081022;第56卷(第21期);第10160–10167页 * |
Synthesis and Biological Activities of Novel Pyrazole Oxime Derivatives Containing a 2-Chloro-5-thiazolyl Moiety;HONG DAI,等;《J. Agric. Food Chem.》;20081030;第56卷(第22期);第10805–10810页 * |
史大斌,等.N-取代-5-磺酰基吡唑肟酯衍生物的合成及生物活性研究.《遵义医学院学报》.2008,第31卷(第03期),第228-230页. |
吡唑肟醚类化合物的合成;肖慧泉,等;《合成化学》;20051231;第13卷(第06期);第600-602页 * |
戴红,等.新型含吡啶环取代的吡唑肟醚类化合物的合成及生物活性研究.《有机化学》.2011,第31卷(第10期),第1662-1667页. |
新型含吡啶环取代的吡唑肟醚类化合物的合成及生物活性研究;戴红,等;《有机化学》;20111031;第31卷(第10期);第1662-1667页 * |
肖慧泉,等.吡唑肟醚类化合物的合成.《合成化学》.2005,第13卷(第06期),第600-602页. |
Also Published As
Publication number | Publication date |
---|---|
CN102675205A (zh) | 2012-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103664689A (zh) | 对癌细胞微管蛋白聚合有抑制作用的一类查尔酮肟衍生物及其制备方法 | |
CN102617391B (zh) | 一种白藜芦醇苯丙烯酰胺类衍生物、其制备方法及其用途 | |
CN102675205B (zh) | 一种吡唑肟醚类化合物及其制备与在抗癌治疗中的应用 | |
CN103664932A (zh) | 一类吲哚接枝噻唑腙类衍生物及其制备方法和对癌细胞微管蛋白聚合的抑制作用 | |
CN106496123B (zh) | 一种二氢吡唑类衍生物及其制备方法和应用 | |
CN103664786A (zh) | 一类水杨醛的二氢吡唑磺胺衍生物的合成及在抗癌药物中的应用 | |
CN105061441A (zh) | 含哌嗪等氮杂环的香豆素并吡唑类化合物及其制备与在抑制肿瘤细胞中的应用 | |
CN105669823A (zh) | 一类含哌嗪骨架的甘草次酸衍生物、其制备方法及应用 | |
CN103588758A (zh) | 一类含1,4-苯并二噁烷骨架的硝基咪唑衍生物的合成、制备及其在抗癌药物中的应用 | |
CN108033913A (zh) | 一种二氢吡唑啉衍生物及其制备方法和应用 | |
CN103254133A (zh) | 二芳基吡唑苯胺类化合物的制备及其在结肠癌治疗中的应用 | |
CN103113304A (zh) | 一种吡唑硫脲类衍生物及其制备方法与用途 | |
CN105461723A (zh) | 酞嗪并[1,2,b]喹唑啉-8-酮化合物及其制备方法和在抗肿瘤药物中的应用 | |
CN104829534A (zh) | 一类含萘环骨架的二氢吡唑吗啉衍生物的制备方法及在抗癌药物中的应用 | |
CN105061440A (zh) | 含乙酰氨基氮杂环的香豆素并吡唑类化合物及其制备与在抑制肿瘤细胞中的应用 | |
CN103709146B (zh) | 一类含苯并咪唑结构的喹啉-4-胺衍生物、其制法及医药用途 | |
CN103664926A (zh) | 一类二氢吡唑噻唑衍生物的合成及在抗癌药物中的应用 | |
CN103804303A (zh) | Egfr小分子抑制剂嘧啶衍生物及其制备方法与用途 | |
CN101735113B (zh) | 一类尿素衍生物及其制法与用途 | |
CN103819408B (zh) | 硝基咪唑衍生物及其制备方法和用途 | |
CN103319431B (zh) | 含2‑巯基苯乙酮的1,3,4‑噁二唑衍生物及其制法与抗肿瘤活性 | |
CN103102284A (zh) | 4-三氟甲基-2,6-二硝基苯水杨醛肟类衍生物的制备及其在抗癌治疗药物中的应用 | |
CN104961683A (zh) | 一类含萘环骨架的二氢吡唑哌嗪衍生物的制备方法及在抗癌药物中的应用 | |
CN102702259A (zh) | 一种吡唑甲基氨基膦酸酯类化合物及其制备与在抗癌中的应用 | |
CN101560175B (zh) | 一类硫脲类衍生物及其制备方法与用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Lv Xianhai Inventor after: Zhu Hailiang Inventor after: Chao Haiqun Inventor after: Sun Jian Inventor before: Lv Xianhai Inventor before: Zhu Hailiang Inventor before: Lu Xiang Inventor before: Sun Jian |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: LV XIANHAI ZHU HAILIANG LU XIANG SUN JIAN TO: LV XIANHAI ZHU HAILIANG CHAOHAIQUN SUN JIAN |
|
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Lv Xianhai Inventor after: Zhu Hailiang Inventor after: Cao Haiqun Inventor after: Sun Jian Inventor before: Lv Xianhai Inventor before: Zhu Hailiang Inventor before: Chao Haiqun Inventor before: Sun Jian |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: LV XIANHAI ZHU HAILIANG CHAO HAIQUN SUN JIAN TO: LV XIANHAI ZHU HAILIANG CAO HAIQUN SUN JIAN |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140820 Termination date: 20150525 |
|
EXPY | Termination of patent right or utility model |